{image_1}Dr. Patrick J. Flynn was selected by the Twin Cities Medical society Foundation Board as this recipient of the 2016 Charles Bolles Bolles-Rogers Award. Dr. P.J. Flynn was nominated by Dr. Joseph Leach on behalf of his colleagues at Minnesota Oncology.
Candidates for this "Physician of Excellence" award are nominated by their colleagues at Twin City area hospitals and/or clinics for achievement or leadership in medicine, contributions to clinical care, teaching and/or research. This candidate is considered to be an outstanding physician by his or her peers.
In a letter to Dr. Flynn notifying him of the award, Twin Cities Medical Society Foundation Chair Chris Johnson, M.D. and Twin Cities Medical Society CEO Sue Schettle noted: "Twin Cities Medical Society Foundation considers this award to be the single, most prestigious local honor that can be given to a physician by their colleagues."
Dr. P.J. Flynn's honor was recognized at the October Minnesota Oncology Board meeting, and the Award will be officially presented to Dr. Flynn in November at a physician event.
"We congratulate P.J. on this honor in observance of his excellent clinical care and outstanding leadership with cancer research in the Twin Cities over many years," said Minnesota Oncology President Dean Gesme, M.D.
Minnesota Oncology physicians Joseph Cardamone, M.D. and Burton Schwartz, M.D. are previous Bolles-Rogers Awardees.
Share
Categories
Tags
Recent Posts
Clinical trials are essential to advancing cancer care. Learn what clinical trials are, how they work, and how they help improve treatment options for patients.
“Minnesota Oncology listens. You are heard. Any concern you have, they do their best to answer it,” she said. “I am so thankful for everyone at Minnesota Oncology – Dr. Vera, Syndey, the schedulers, infusion nurses, everyone at the Maple Grove clinic. You feel at home there, which is hard to do when you are going through treatment. Minnesota Oncology treats you like family.”
Testicular cancer happens when cancer cells grow in one or both testicles. It is not very common. About 1 in 250 men will get testicular cancer during their lifetime.